Results 181 to 190 of about 21,372 (208)

Ibrutinib plus venetoclax for relapsed/refractory mantle cell lymphoma: Final analysis of the phase 3 SYMPATICO study. [PDF]

Br J Haematol
Wang M, Jurczak W, Trneny M, Belada D, Wrobel T, Ghosh N, Keating MM, van Meerten T, Alvarez RF, von Keudell G, Thieblemont C, Peyrade F, Andre M, Hoffmann M, Szafer-Glusman E, Lin J, Dean JP, Neuenburg JK, Tam CS.   +18 more
europepmc   +1 more source

Controversies in the Management of AML in Older Patients: A Canadian Perspective. [PDF]

Curr Oncol
Schuh AC, Brandwein J, Elsawy M, Sanford D, Leber B.   +4 more
europepmc   +1 more source

Successful induction of remission with azacitidine, venetoclax, and dasatinib followed by allogeneic hematopoietic stem cell transplantation in a patient with Philadelphia chromosome-positive mixed phenotype acute leukemia (B/myeloid): a case report. [PDF]

Front Med (Lausanne)
Zhang J, Huang Y, Luo L, Huang K, Pang Y.   +4 more
europepmc   +1 more source

Evaluation of venetoclax and hypomethylating agent combination therapy in acute myeloid leukemia: a real-life, single-center experience. [PDF]

BMC Cancer
Oral K, Uysal A.
europepmc   +1 more source

Early venetoclax dose escalation at minimal residual disease progression may benefit selected acute myeloid leukaemia patients. [PDF]

Br J Haematol
Kytölä S, Partanen A, Kuusisto MEL, Koskela S, Holopainen A, Vänttinen I, Ruokoranta T, Ettala P, Rimpiläinen J, Siitonen T, Pyörälä M, Kuusanmäki H, Kontro M.   +12 more
europepmc   +1 more source

Integrative Single-Cell and Spatial Transcriptomic Analyses Link Arachidonic Acid Metabolic Reprogramming to Proneural-to-Mesenchymal State Transition in Glioblastoma. [PDF]

Biomedicines
Peng S, Wen Z, Cai XT.
europepmc   +1 more source

Erratum: Brem EA, Shieh K, Juarez D, et al. A phase 1 study adding pitavastatin to venetoclax therapy in AML and CLL/SLL: a mechanism-based drug repurposing strategy. <i>Blood Neoplasia</i>. 2024;1(4):100036. [PDF]

Blood Neoplasia
europepmc   +1 more source

Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination Therapies

Cancers, 2022
SIMPLE SUMMARY: Venetoclax has proven to be a promising therapy for newly diagnosed, relapsed and refractory AML patients ineligible for induction chemotherapy.
David de Leeuw, Linda Smit
exaly   +2 more sources

Venetoclax resistance: mechanistic insights and future strategies

Cancer Drug Resistance (Alhambra, Calif ), 2022
Acute myeloid leukemia (AML) is historically associated with poor prognosis, especially in older AML patients unfit for intensive chemotherapy. The development of Venetoclax, a potent oral BH3 (BCL-2 homology domain 3) mimetic, has transformed the AML ...
Marina Konopleva, Kunhwa Kim, Faustine Ong   +2 more
exaly   +1 more source